The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Intersection · Compounds × needs a source

Compounds topics tagged needs a source

Topics in Compounds carrying the tag needs a source. A claim in this topic has been challenged and not yet supported.

50 topics

TopicParticipantsRepliesViewsActivity
GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion
On the subject in the title: GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Working notes rather than a conclusion. I have seen STEP 2 ( Lancet , 2021) cited in support of…
PPNKRVHBMM+47 53 6.9k 2h
Reading a rodent study on a secretagogue without over-extrapolating — the long version
Reading a rodent study on a secretagogue without over-extrapolating — the long version — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support…
CDDBANKBMA+59 66 30k 4h
Stability of BPC-157 in solution: what has been measured — one year on
On the subject in the title: Stability of BPC-157 in solution: what has been measured — one year on Working notes rather than a conclusion. Comparing STEP 2 ( Lancet , 2021) with STEP 1 ( N Engl J Med , 2021)…
KFNASCPWVB+84 98 7.8k 18h
AOD-9604 and the fragment hypothesis, revisited — does this still hold?
The question in the title: AOD-9604 and the fragment hypothesis, revisited — does this still hold? I will give what I have already checked below so nobody repeats it. Comparing FLOW ( N Engl J Med , 2024)…
NLKKNRPFI+7 11 31k 19h
Publication patterns in the BPC-157 literature, examined
Posting this under the heading it deserves: Publication patterns in the BPC-157 literature, examined Everything below is what sits behind that. I have seen SURPASS-2 ( N Engl J Med , 2021) cited in support of…
MMMHEIDVBO+40 45 3.4k 21h
CJC-1295 with and without DAC: what the modification does
On the subject in the title: CJC-1295 with and without DAC: what the modification does Working notes rather than a conclusion. Comparing PIONEER 6 ( N Engl J Med , 2019) with SURMOUNT-OSA ( N Engl J Med ,…
MSNCDHEHNE+117 123 5.6k 22h
What would change my mind about repair peptides: a specific answer
What would change my mind about repair peptides: a specific answer — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4 ( JAMA , 2024). Please…
MMJMEKCMA+26 30 1.1k 23h
BPC-157: what the rodent literature actually shows, and what it does not — does this still hold?
The question in the title: BPC-157: what the rodent literature actually shows, and what it does not — does this still hold? I will give what I have already checked below so nobody repeats it. I have seen…
ASBSMCSBLS+6 10 3.1k 1d
Why the absence of controlled human data on BPC-157 matters more than people admit
Why the absence of controlled human data on BPC-157 matters more than people admit — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing STEP 8 ( JAMA , 2022) with…
CMVMPFNBHF+60 66 16k 1d
Research-use-only status: what it means legally and practically
Research-use-only status: what it means legally and practically Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med , 2024) cited in…
KFKLVSHVAF+72 81 44k 1d
Why catalogue breadth is not evidence of anything
Why catalogue breadth is not evidence of anything I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a claim I…
CBKAV 2 38k 2d
Evidence quality in the secretagogue literature: an honest assessment
Evidence quality in the secretagogue literature: an honest assessment Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURMOUNT-OSA ( N Engl J Med , 2024) with STEP…
SSSVK 2 25k 9d
Secretagogues and glucose tolerance: the mechanistic concern
On the subject in the title: Secretagogues and glucose tolerance: the mechanistic concern Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…
INRDMDOVFF+64 70 52k 17d
Why this subcategory is stricter about sourcing than most
Asking directly, because I could not find a straight answer: Why this subcategory is stricter about sourcing than most Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before posting; the…
DOCAEFRESC+48 52 617 21d
Naming conventions for research peptides and the confusion they cause
Posting this under the heading it deserves: Naming conventions for research peptides and the confusion they cause Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022) with STEP 1 ( N…
ATNFPNDA+21 25 4.9k 22d
Stability of BPC-157 in solution: what has been measured
Stability of BPC-157 in solution: what has been measured — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with FLOW ( N Engl J Med , 2024) and finding the…
AKEFSS 2 805 30d
Analytical identity of BPC-157: a 15-mer with a simple mass — does this still hold?
Analytical identity of BPC-157: a 15-mer with a simple mass — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURPASS-2 ( N Engl J…
WRNDTHFBV+28 33 1.6k 1mo
Follow-up: Evidence quality in the secretagogue literature: an honest assessment
On the subject in the title: Evidence quality in the secretagogue literature: an honest assessment Working notes rather than a conclusion. Comparing PIONEER 6 ( N Engl J Med , 2019) with LEADER ( N Engl J Med…
BSHRTMNCI+20 24 18k 4mo
IGF-1 as a surrogate endpoint and its limitations
IGF-1 as a surrogate endpoint and its limitations Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a claim I do not…
OCSLTDCJN+5 9 35k 4mo
Oral versus injected administration claims for BPC-157
Oral versus injected administration claims for BPC-157 — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do not think…
RMAAMMRST+20 24 47k 4mo
Coming back to: Reading a supplier's product description as a marketing document
Reading a supplier's product description as a marketing document Writing it up because I had to work it out twice and would rather nobody else did. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in…
HBELCVHNDN+35 39 688 5mo
AOD-9604 and the fragment hypothesis, revisited
Posting this under the heading it deserves: AOD-9604 and the fragment hypothesis, revisited Everything below is what sits behind that. Comparing SURPASS-2 ( N Engl J Med , 2021) with SUSTAIN 6 ( N Engl J Med…
ARCDJBMRBR+40 44 2.8k 6mo
About the Other compounds category
Anything not covered by a dedicated subcategory, including research-use-only material with no human data. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…
KJMMYSDK+8 12 51k 7mo
Sequence verification for an obscure compound: how it is done — what changed since
On the subject in the title: Sequence verification for an obscure compound: how it is done — what changed since Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please…
TNDBSOLGHF+100 108 1.3k 8mo
Reading a supplier's product description as a marketing document
On the subject in the title: Reading a supplier's product description as a marketing document Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support of a claim I…
SVTVMRZOIN+86 97 62k 8mo
Research-use-only status: what it means legally and practically — does this still hold?
Asking directly, because I could not find a straight answer: Research-use-only status: what it means legally and practically — does this still hold? Session topic: SELECT ( N Engl J Med , 2023). Please read…
DBETRT 2 309 9mo
Compounds this community declines to help with, and why
Compounds this community declines to help with, and why — setting out what I have, and where I think it stops being reliable. Comparing LEADER ( N Engl J Med , 2016) with SCALE ( N Engl J Med , 2015) and…
MKJSMSRFF+81 87 35k 10mo
Why catalogue breadth is not evidence of anything — what changed since
Asking directly, because I could not find a straight answer: Why catalogue breadth is not evidence of anything — what changed since Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…
NEHFDBBKLG+62 66 26k 10mo
Reading a rodent study on a secretagogue without over-extrapolating
Posting this under the heading it deserves: Reading a rodent study on a secretagogue without over-extrapolating Everything below is what sits behind that. I have seen STEP 8 ( JAMA , 2022) cited in support of…
EKLLTVOF+50 54 32k 10mo
BPC-157: what the rodent literature actually shows, and what it does not
BPC-157: what the rodent literature actually shows, and what it does not — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016) cited in support of a…
PILSTMIAK+44 48 3k 10mo